glp-1 alzheimer's 2025 Role of glucagon-like peptide-1 receptor agonists in disease and Parkinson's disease | Journal of Biomedical Science GLP-1 receptor agonists reduce dementia

10.1056/nejmoa1603827 46 MeurotC.MartinC.SudreL.BretonJ.BougaultC.RattenbachR.et al (2022)

When administered, Semaglutide binds to GLP-1 receptors, stimulating the pancreas to enhance insulin secretion in response to meals, while simultaneously reducing glucagon release, helping to prevent excessive blood sugar levels

The FDA has issued public warnings about dosing errors and adverse events involving compounded semaglutide and tirzepatide - with more than 1,700 adverse events linked to compounded semaglutide and tirzepatide combined as of May 21, 2026, according to FDA's published adverse event data

Longer wear does not increase benefits

The GLP-1 space is really heating up